Does EPCORITAMAB-BYSP Cause Diffuse large b-cell lymphoma refractory? 198 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 198 reports of Diffuse large b-cell lymphoma refractory have been filed in association with EPCORITAMAB-BYSP. This represents 20.3% of all adverse event reports for EPCORITAMAB-BYSP.
198
Reports of Diffuse large b-cell lymphoma refractory with EPCORITAMAB-BYSP
20.3%
of all EPCORITAMAB-BYSP reports
101
Deaths
25
Hospitalizations
How Dangerous Is Diffuse large b-cell lymphoma refractory From EPCORITAMAB-BYSP?
Of the 198 reports, 101 (51.0%) resulted in death, 25 (12.6%) required hospitalization, and 7 (3.5%) were considered life-threatening.
Is Diffuse large b-cell lymphoma refractory Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EPCORITAMAB-BYSP. However, 198 reports have been filed with the FAERS database.
What Other Side Effects Does EPCORITAMAB-BYSP Cause?
Cytokine release syndrome (369)
Diffuse large b-cell lymphoma (206)
Pyrexia (79)
Immune effector cell-associated neurotoxicity syndrome (77)
Covid-19 (39)
Neutrophil count decreased (35)
Hypogammaglobulinaemia (32)
Platelet count decreased (32)
Cytomegalovirus infection (31)
Pneumonia (29)
What Other Drugs Cause Diffuse large b-cell lymphoma refractory?
RITUXIMAB (461)
CYCLOPHOSPHAMIDE (360)
DOXORUBICIN (345)
VINCRISTINE (331)
ETOPOSIDE (244)
PREDNISONE (214)
CYTARABINE (193)
DEXAMETHASONE (170)
CISPLATIN (156)
IFOSFAMIDE (154)
Which EPCORITAMAB-BYSP Alternatives Have Lower Diffuse large b-cell lymphoma refractory Risk?
EPCORITAMAB-BYSP vs EPERISONE
EPCORITAMAB-BYSP vs EPHEDRINE
EPCORITAMAB-BYSP vs EPINASTINE
EPCORITAMAB-BYSP vs EPINEPHRINE
EPCORITAMAB-BYSP vs EPINEPHRINE\LIDOCAINE